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Paravalvular regurgitation (PVR) signiﬁcantly increases mortality
from 35.3% for mild PVR to 60.8% for moderate-to-severe PVR as
reported in the PARTNER trial in 3-year transcatheter aortic valve
implantation (TAVI) outcomes [1].
PVR results from incomplete apposition of the prosthesis to the
aortic annulus. Recognizing the underlying mechanism is import-
ant to improve TAVI outcomes further. Understanding the ethol-
ogy of what might seem a simple equation of two variables—ﬁrst,
the aortic valve and root complex and second, the TAVI device—is
a challenging undertaking.
Additional variables add to the complexity leading to PVR after
TAVI. Adequate imaging focusing not only on annular diameter,
but also on circularity, distribution of aortic valve calciﬁcations or
left ventricular outﬂow tract (LVOT)/aortic root angulation,
impacts on the choice of device size and type. Mechanical prop-
erties and stent design as well as access direction or delivery strat-
egies are further determinants of PVR and subsequently survival
outcomes. Assessment and quantiﬁcation of PVR are not standar-
dized, and the degree of regurgitation of various studies is difﬁcult
to compare. At present, even the adoption of the Valve Academic
Research Consortium (VARC) consensus document [2], the stand-
ard classiﬁcation used to describe regurgitation in native valves,
does not guarantee comparable PVR assessments. Multi-located
eccentric jets make quantitative echocardiographic evaluation dif-
ﬁcult. Stent and calciﬁcation induced shadowing interfere with
ﬂow signals and transthoracic two-dimensional echocardiography
might underestimate the degree of regurgitation. When interpreting
the present meta-analysis data, those facts need to be considered
carefully.
In this issue, O’Sullivan et al. [3] reviewed the literature reporting
on PVR after TAVI. Nine publications including nearly 6000 patients
were identiﬁed to report PVR data of either the balloon-expandable
Edwards Sapien (ES; four publications) or the self-expanding Med-
tronic Corevalve (MCV) device (two publications) or both devices
(seven publications).
To support their observational conclusion that the self-
expanding MCV device has a signiﬁcantly higher rate of PVR com-
pared with the balloon-expandable ES valve, the authors deﬁned
two variables: ﬁrst, modiﬁable factors being technological issues
and second, non-modiﬁable factors being anatomical considera-
tions leading to PVR.
In particular, as modiﬁable factors were identiﬁed: stent design
including material properties and construction particularities, de-
ployment position and prosthesis/annulus mismatch including
sizing. Non-modiﬁable factors predisposing to PVR were the angle
between LVOT and aortic root as well as aortic valve calciﬁcations.
Even though the France 2 register [4] and the UK TAVI registers [5]
indicate that the antegrade transapical TAVI approach has a signiﬁ-
cantly lower incidence of PVR when compared with all retrograde
routes, the authors did not analyse the impact of access route on
PVR in this paper.
The authors primarily discuss stent designs, material character-
istics and deployment technique as modiﬁable factors for PVR. An
MCV self-expanding nitinol stent having continuous radial expan-
sion forces results in higher compliance in the non-circular anatomy.
In comparison, an ES stainless steel stent exhibits a higher stiffness
better withstanding the compressive forces of the calciﬁed valve
resulting in high degree of circularity in 98.5% of implants [6]. Valve
positioning and prosthesis/annulus incongruence are further elabo-
rated under valve-related modiﬁable factors leading to PVR.
Despite the evidence for increased PVR and the intrinsic insight
into the mechanistic origin of PVR in the MCV device, there are
limitations to be considered. The absence of randomized studies
comparing the two devices in all-comers presents an important
draw back. The choice of device type might be inﬂuenced by ana-
tomical considerations and site-speciﬁc consideration, for example
favouring a self-expanding device in a massively calciﬁed aortic
valve. Accordingly, an ES device is favoured in the hostile setting
of strong LVOT/aortic root angulation. Both conditions might lead
to increased PVR in either device and induce a device selection
bias.
Mechanistic insights into PVR after TAVI set aside, the authors in
their meta-analysis found a signiﬁcant increase in PVR in patients
undergoing an MCV implantation compared with those undergo-
ing an ES implantation. Further studies are mandatory to conﬁrm
the present ﬁndings.
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PVR after TAVI remains an unresolved driver of independent
signiﬁcantly higher mortality. All efforts should be made to elimin-
ate PVR before expanding TAVI indication to lower risk and younger
patients. The solution to a technical problem often is more technol-
ogy. Next-generation TAVI devices, improved imaging and a percu-
taneous antegrade transapical TAVI platform might contribute to
reducing TAVI-related PVR.
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